"Precision medicine" is an anti-cancer treatment strategy in which doctors use genetic or other tests to identify vulnerabilities in an individual's cancer subtype. Winship Cancer Institute researchers have been figuring out how to apply this strategy to multiple myeloma, with respect to one promising drug called venetoclax, in a way that can benefit the most patients.
"One of our main goals is to identify a better biomarker to predict patient response to venetoclax," says Winship researcher Vikas Gupta, MD, PhD, lead author of a paper published in Blood.
Gupta is working together with Winship hematologist Jonathan Kaufman, MD, and researcher Larry Boise, PhD, associate director for education and training, to translate insights about myeloma cells into advances for patient care.
Gupta is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.